Vol 9, No 3 (2018)
Case report
Published online: 2018-10-17

open access

Page views 684
Article views/downloads 906
Get Citation

Connect on Social Media

Connect on Social Media

How we treat a patient with intermediate-risk light chain amyloidosis? The role of doxycycline in cardiac amyloidosis.

Aleksander Salomon-Perzyński1, Agnieszka Końska1, Bartosz Puła1, Justyna Łyczkowska-Piotrowska2, Krzysztof Jamroziak1
Hematologia 2018;9(3):245-253.

Abstract

Treatment of patients with light chain amyloidosis (AL amyloidosis) is a challenge in routine clinical practice. Although deep and durable hematologic response is crucial for the success of the therapy, in this group of patients the proper conduct of supportive care becomes particularly important. Because AL amyloidosis is an interdisciplinary disease entity, the therapeutic process should be coordinated by an interdisciplinary team consisting of a hematologist, cardiologist, nephrologist, gastroenterologist, neurologist and clinical dietician. In this paper, we present a strategy for treating a patient with a newly diagnosed systemic intermediate-risk AL amyloidosis with cardiac involvement in the Department of Hematology of the Institute of Hematology and Transfusion Medicine in Warsaw, in which, apart of standard chemotherapy, doxycycline was used.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Milani P, Merlini G, Palladini G. Light Chain Amyloidosis. Mediterr J Hematol Infect Dis. 2018; 10(1): e2018022.
  2. Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018; 2(10): 1046–1053.
  3. Jamroziak K, Milani P, Puła B, et al. Diagnostyka i leczenie amyloidozy AL. Hematologia. 2018; 9(3).
  4. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004; 22: 3751-3757. J Clin Oncol. 2004; 22(18): 3751–3757.
  5. Sidiqi MH, Aljama MA, Buadi FK, et al. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. J Clin Oncol. 2018; 36(13): 1323–1329.
  6. Sanchorawala V, Sun F, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015; 126(20): 2345–2347.
  7. Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016; 128(2): 159–168.
  8. Dispenzieri A, Buadi F, Kumar SK, et al. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015; 90(8): 1054–1081.
  9. Kastritis E, Leleu X, Arnulf B, et al. A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood. 2016; 128(22): e59–e60.
  10. Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015; 126(5): 612–615.
  11. Gavriatopoulou M, Musto P, Caers Jo, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018; 32(9): 1883–1898.
  12. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013; 121(26): 5124–5130.
  13. Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013; 121(17): 3420–3427.
  14. Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014; 99(9): 1479–1485.
  15. Łyczkowska-Piotrowska J, Salomon-Perzyński A, Końska A, et al. Doksycyklina w terapii amyloidozy układowej z zajęciem serca. Hematologia. 2018; 9(3).
  16. Ward JE, Ren R, Toraldo G, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011; 118(25): 6610–6617.
  17. Imperlini E, Gnecchi M, Rognoni P, et al. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep. 2017; 7(1): 15661.
  18. Diomede L, Rognoni P, Lavatelli F, et al. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood. 2014; 123(23): 3543–3552.
  19. Kumar SK, Dispenzieri A, Lacy MQ, et al. Doxycycline used as post-transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell trans- plantation. Blood. 2012; 120(21): 3138.
  20. Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 2017; 7(3): e546.
  21. D'Souza A, Flynn K, Chhabra S, et al. Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemp Clin Trials Commun. 2017; 8: 33–38.
  22. Dahm CN, Cornell RF, Lenihan DJ. Advances in Treatment of Cardiac Amyloid. Curr Treat Options Cardiovasc Med. 2018; 20(5): 37.
  23. Smith W, Wan H, Much D, et al. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Clin Auton Res. 2016; 26(4): 269–277.



Hematology in Clinical Practice